Share Name Share Symbol Market Type Share ISIN Share Description
Futura Medical LSE:FUM London Ordinary Share GB0033278473 ORD 0.2P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.50p -0.87% 56.75p 56.50p 57.00p 57.25p 56.75p 57.25p 91,900.00 10:54:43
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.0 -6.1 -5.1 - 68.18

Futura Medical (FUM) Latest News

More Futura Medical News
Futura Medical Takeover Rumours

Futura Medical (FUM) Share Charts

1 Year Futura Medical Chart

1 Year Futura Medical Chart

1 Month Futura Medical Chart

1 Month Futura Medical Chart

Intraday Futura Medical Chart

Intraday Futura Medical Chart

Futura Medical (FUM) Discussions and Chat

Futura Medical Forums and Chat

Date Time Title Posts
02/12/201613:27FUM delivering on sex,pain and rock'n'roll11,414.00
30/11/201619:16FUTURA a winner for 20152,099.00
19/9/201613:19www.bluediamondcondom.com41.00
21/6/201607:43fum reality1.00
07/11/201412:19fum-

Add a New Thread

Futura Medical (FUM) Most Recent Trades

No Trades
Trade Time Trade Price Trade Size Trade Value Trade Type
View all Futura Medical trades in real-time

Futura Medical (FUM) Top Chat Posts

DateSubject
03/12/2016
08:20
Futura Medical Daily Update: Futura Medical is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker FUM. The last closing price for Futura Medical was 57.25p.
Futura Medical has a 4 week average price of 58.13p and a 12 week average price of 62.75p.
The 1 year high share price is 96.25p while the 1 year low share price is currently 14.50p.
There are currently 120,144,950 shares in issue and the average daily traded volume is 201,790 shares. The market capitalisation of Futura Medical is £68,182,259.13.
16/11/2016
12:37
loobrush: Med2002 has the potential for a double whammy with over the counter(OTC) for low dose and prescription only for the high dose.I don't know which will be biggest,but it seems to me that the OTC version could be miles bigger as people will try this whether they have a problem or not.If the OTC version was put on sale now a lot of men would try it just to see what happens let alone those with a problem who dont want to see a doctor.FUM'S value is certainly higher than todays share price and my own valuation if the final trial goes well is that the share price will be over £3.00 by this time next year. Next we should hear first launch news on CSD500 before Xmas and European manufacturing approval-then into next year further launches across the globe-so plenty of news coming to and as things progress share price will move up accordingly.
01/11/2016
11:51
loobrush: lse News soon Today 11:49 News on start of global roll out of CSD 500 starting in middle east due out imminently plus european approval of 18 month shelf life and first licencing of pain portfolio,plus could be other news. So lots of news and progress expected which could come at any time. Share price is drifting as impatient holders sell, however, news will soon push the share price higher and sellers now will regret it in my view.
25/10/2016
12:34
neo26: Ready to go again? Futura Medical tipped to rally Share 09:11 09 Oct 2016 The dust has settled after August's 300% rally, but technical analysis suggests the price will move higher again. Trader's delight: Futura shares could reach 100p to 120p in the coming months. As it is a £60mln valued company with plans to launch a disruptive new product into a multibillion dollar market, it is probably not shocking to hear an expert say shares in Futura Medical Plc (LON:FUM) ought to go higher. Futura’s price jumped some 300% in August – thanks to a breakthrough with its new erectile dysfunction product – and now, following a pull-back and a pause for breath it is predicted that there can be a fresh rally. Technical analyst Zak Mir has noted that Futura had seen a significant transformation in recent weeks and he highlighted that the share price chart now showed a ‘good consolidation’ since the summer breakout. “The shares aren’t even overbought now, they’ve cooled off” Mir said in a Tips TV segment for Proactive Investors. WATCH Zak Mir's analysis right now The chart guru believes the share can push on to reach between 100p to 120p over the next three to six months – and that’s a target that he says is valid whilst the price holds above the 50-day average, around the 45p mark. Mir adds, however, that when it comes to timing an entry technically minded traders may be conservative. “I think you probably wait if you’re really cautious. You wait for the RSI to go back towards the oversold area. So maybe there’s a move below 60p that puts the RSI lower. You’ll feel at least that you’re not paying too much money near the top. “But we have come back already, we are off the top already. So from these areas probably going in stages is the right way.” A breakthrough The uptick in Futura’s fortunes coincided with some very positive data from a 232-strong trial of its erectile dysfunction drug, MED2002. It boasts one advantage that marks it out from the current treatments - pills such as Viagra and Cialis - and that’s speed of onset. For while the little blue pill can take up to 30 minutes to work its magic, Eroxon, a gel applied directly to the nether regions, takes effect in as little as five minutes. Stockbroker N+1 Singer, citing Futura’s own market research, N+1 suggests that based on this superior onset of action, the safety profile and the switch to selling Eroxon over the counter, annual revenues could be in excess of £380mln (US$500mln). Sales of drugs treating erectile dysfunction currently stands at £3.8bn (US$5bn). If the new discovery does achieve anywhere near its potential, then the bout of profit-taking witnessed in recent weeks may be misplaced. Futura isn’t a one-trick pony. The same delivery mechanism used for Eroxon, a gel that penetrates the skin, could be used to deliver all sorts of drugs, including pain relief. The company has, crucially, solved the shelf-life problems with its CSD500 condoms, designed to help men maintain an erection and maximise penile size. Regulatory submissions to enable an extended shelf life of at least 18 months have been filed for both its European manufacturer and for TTK Protective Devices Limited, the Indian manufacturer with whom it has also signed a distribution agreement. Futura is also making progress with out-licensing talks for the topical pain relief gels, and it is now at the heads-of-terms stage with a number of potential partners. In a recent Proactive Investors interview Futura chief executive James Barder said: “We’ve already got approval for the product in Europe, but that was with one German manufacturer where we currently have a shelf life of twelve months,” “The problem with that is that most retailers want to have at least twelve months shelf life when the product hits the store, so bearing in mind the logistics of the supply chain you’re not going to be able to achieve that unless you’ve got eighteen months.” “Now that we’ve got that it will help us move forward.” Barder added that the company expects, and is already seeing, a lot of interest in the product.
07/10/2016
17:08
isaready: Ready to go again? Futura Medical tipped to rally Share 09:11 07 Oct 2016 The dust has settled after August's 300% rally, but technical analysis suggests the price will move higher again. Happy trader Trader's delight: Futura shares could reach 100p to 120p in the coming months. As it is a £60mln valued company with plans to launch a disruptive new product into a multibillion dollar market, it is probably not shocking to hear an expert say shares in Futura Medical Plc (LON:FUM) ought to go higher. Futura’s price jumped some 300% in August – thanks to a breakthrough with its new erectile dysfunction product – and now, following a pull-back and a pause for breath it is predicted that there can be a fresh rally. Technical analyst Zak Mir has noted that Futura had seen a significant transformation in recent weeks and he highlighted that the share price chart now showed a ‘good consolidation’ since the summer breakout. “The shares aren’t even overbought now, they’ve cooled off” Mir said in a Tips TV segment for Proactive Investors. WATCH Zak Mir's analysis right now The chart guru believes the share can push on to reach between 100p to 120p over the next three to six months – and that’s a target that he says is valid whilst the price holds above the 50-day average, around the 45p mark. Mir adds, however, that when it comes to timing an entry technically minded traders may be conservative. “I think you probably wait if you’re really cautious. You wait for the RSI to go back towards the oversold area. So maybe there’s a move below 60p that puts the RSI lower. You’ll feel at least that you’re not paying too much money near the top. “But we have come back already, we are off the top already. So from these areas probably going in stages is the right way.” A breakthrough The uptick in Futura’s fortunes coincided with some very positive data from a 232-strong trial of its erectile dysfunction drug, MED2002. It boasts one advantage that marks it out from the current treatments - pills such as Viagra and Cialis - and that’s speed of onset. For while the little blue pill can take up to 30 minutes to work its magic, Eroxon, a gel applied directly to the nether regions, takes effect in as little as five minutes. Stockbroker N+1 Singer, citing Futura’s own market research, N+1 suggests that based on this superior onset of action, the safety profile and the switch to selling Eroxon over the counter, annual revenues could be in excess of £380mln (US$500mln). Sales of drugs treating erectile dysfunction currently stands at £3.8bn (US$5bn). If the new discovery does achieve anywhere near its potential, then the bout of profit-taking witnessed in recent weeks may be misplaced. Futura isn’t a one-trick pony. The same delivery mechanism used for Eroxon, a gel that penetrates the skin, could be used to deliver all sorts of drugs, including pain relief. The company has, crucially, solved the shelf-life problems with its CSD500 condoms, designed to help men maintain an erection and maximise penile size. Regulatory submissions to enable an extended shelf life of at least 18 months have been filed for both its European manufacturer and for TTK Protective Devices Limited, the Indian manufacturer with whom it has also signed a distribution agreement. Futura is also making progress with out-licensing talks for the topical pain relief gels, and it is now at the heads-of-terms stage with a number of potential partners. In a recent Proactive Investors interview Futura chief executive James Barder said: “We’ve already got approval for the product in Europe, but that was with one German manufacturer where we currently have a shelf life of twelve months,” “The problem with that is that most retailers want to have at least twelve months shelf life when the product hits the store, so bearing in mind the logistics of the supply chain you’re not going to be able to achieve that unless you’ve got eighteen months.” “Now that we’ve got that it will help us move forward.” Barder added that the company expects, and is already seeing, a lot of interest in the product.
03/10/2016
07:47
j777j: Share price is lower than it was three years ago and yet the co has multiple products at commercialisation stage. JB was asked about the cash situation in a recent video interview ,where he hinted at it not being an issue because they will be receiving upfront,milestone and royalty payments,presumably this year. The share price should be multiples higher. Gla Ps Anything but holding pounds sterling must be a good bet.
23/9/2016
08:45
isaready: This share price will be news driven, clearly. Any sign of actual possible deals, real cashflow flowing in, will move the share price. All we can do is wait and see what will happen and when. I am not sure what the broker note will show other than what we know. They may hold back from ramping it with a price unless they have real info on possible monetary information on possible deals. Hopefully we will see dble bottom and a nice bounce soon enough.
13/9/2016
08:06
j777j: Re 1147 -Clown This interesting too on top of a $500 million market for the erectogenic gel Pain gel Our objective is for our products to be best in class. The rationale for this is that the National Institute for Health and Care Excellence (NICE) gives clear guidance to physicians to prescribe topical NSAIDs in the first instance for joint pain associated with osteoarthritis, in preference to oral NSAIDs, owing to concerns on the long term use of oral NSAIDs. This means that the best-in-class topical treatment should be the first choice for doctors in the initial treatment of pain and therefore represents a substantial opportunity in a market with global sales estimated at US$2.9 billion. Condom 10% of a $6 billion market do the maths. $500 million Erectogenic gel market share $2.9 billion Pain gel market share $600 million condom market share 2.5% royalties would be $100 million a year to Futura On 10X that would be a 740p share price On 15X you are at 1140p share price gla
08/9/2016
23:35
weildy2: What is the shelf life of THIS product ? FUM screwed up and were less than open about the problems with CSD500. Whilst I am delighted with the significant rise in the share price, I would be VERY wary of committing further funds. I have been in this share now for six years (please feel free to check my posting history) and I hold a significant number of shares. I am not a de-ramper, I certainly don't want to shoot myself in the foot, but please don't get carried away with flights of fantasy. Check the history of FUM before you commit your hard earned cash. As I said, I am delighted with the rise in the SP, but those of you new to FUM, please be cautious. FUM do not have a reputation for openness and have misled us in the past.
26/11/2015
15:03
lbo: That is a fair criticism in light of the disappointing share price performance. But I remember no shareholders proposed any resolutions at the AGM regarding the Board, its remuneration or share price performance? Why is that? I do remember one or two posters on here said they gave the Board a hard time in Q&A but I did not see any sign of shareholders looking for change on the Board of Directors. So it would seem to me more would be gained by asking shareholders why they are seemingly happy with progress and the share price and taking no action. Or maybe most on here are not even shareholders anymore but disgruntled small PIs who invested when Futura was overhyped and are now very bitter. I do recollect a lot of posters on here linked to Iofina which I also see was even more overhyped. So this Q&A now would be more of an informative and elightening process. We have even had Hendersons increasing their shareholding during this time. Why have they taken a seemingly opposing view of support? Is it because they are buying in at more realistic valuation and after more real progress has been made in products terms? But perhaps the support for the Board will change by the time of the next AGM or even before if the share price does not perform as well as the faith Mr Barder seems to continue to have in Futura. Time will tell who is right and who is wrong and who will be rewarded by showing support or who may suffer irrecoverable financial loss. I would also say that it might be unfair to say he has not a lot to loose also now. Because if he does not perform by the next AGM in terms of share price then he will surely be seen by all as having failed and not just by shareholders. And by this I refer to his own family who I believe also have a substantial shareholding and vested interest in Futura.
13/11/2013
09:39
sceptic bull: Looking to get back into the small cap markets and I like the look of FUM as one of many many candidates to invest. Attractions: The product will sell itself regardless of marketing ability of partner with plenty of mainstream media coverage. Low cost base of Company therefore any funding will not be significant. If the product works as described then it will get a good % of the market The IP. The main players would have tried very hard to produce their own in-house OTC product but clearly they haven't been able to. Eddison's market share projections and target share price look conservative. Question marks Trial was quite limited. 100 participants. Why no follow up trial to assist marketing claims? How conclusive was the trial? I doubt if this is a big issue but a further conclusive trial would have given me more confidence. If this product works then FUM will get a very significant share of the market. Why did RB relinquish? Not especially important as big companies can make silly decisions. Drop in share price. Are FUM doing a placing? Markets for funding small caps usually exact a discount. Although if reason for drop is some placing leak then I doubt it has further to fall. Despite being in control of production issues FUM cannot control launch date for CSD Limited progress on pain relief products so FUM share price is very reliant on CSD500 Any potential competition. Unlikely as there has been plenty of time to produce something. How good is the board of directors and especially the CEO? Seems competent but not over inspiring.
Futura Medical share price data is direct from the London Stock Exchange
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:31 V: D:20161203 17:46:32